Equity Research Biotechnology

Should You Buy Recursion Pharmaceuticals, Inc. Stock in 2026?

By CirclFi Research Team · · 9/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Recursion Pharmaceuticals, Inc. (RXRX) occupies a solid middle-ground position with a Quality of Company score of 6.7/10. At the current market price of $2.95, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.

The short answer: 1 of 9 CirclFi valuation models project upside for Recursion Pharmaceuticals, Inc. (RXRX) at $2.94 — the model consensus leans bearish, with a Quality Score of 6.7/10 and Value-Trap risk of 37/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 8 of 9 models suggest overvaluation — majority bearish
  • Quality Score: 6.7/10 — Moderate — mixed signals
  • Value Trap Risk: 37/100 — Low — manageable risk
  • Fair Value Range: $0.12 – $2.98 (2353% spread)

Bullish Models

1 / 9

Bearish Models

8 / 9

Quality Score

6.7 /10

Moderate — mixed signals

Value Trap Risk

37 /100
Low

Low — manageable risk

Model Consensus

9 /13
Active Models

Avg. confidence: 26%

Investment Thesis

The Bull Case

Target: $2.98 (+1.0% upside)

  • Industry tailwind: first-mover advantage in novel targets could provide meaningful support for Recursion Pharmaceuticals, Inc.'s revenue and margin trajectory in the Biotechnology space.

The Bear Case

Target: $0.12 (-95.9%)

  • According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.12 (-95.9%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +96.9% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: competitive pipeline overlap represents a meaningful risk for Recursion Pharmaceuticals, Inc. and its Biotechnology peers.

Peer Benchmarking

ADMA ADMA Biologics Inc
10.0
CPRX Catalyst Pharmaceuti
10.0
EXEL Exelixis, Inc.
10.0
HALO Halozyme Therapeutic
10.0
HRMY Harmony Biosciences
10.0

See full Biotechnology rankings →

Valuation Divergence

Spread

2353%

Fair Value Range

$0.12 – $2.98

A 2353% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

FTNN

$2.98 (+1.0%)

Most Bearish

ML-RIV

$0.12 (-95.9%)

Key Risk Factors

Model Disagreement

2353% spread signals high variance in projections.

Bearish Consensus

8/9 models suggest overvaluation.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View RXRX Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Recursion Pharmaceuticals, Inc. at $2.95. 7/9 models flag overvaluation, composite fair value sits at $1.62 (-45.0%), and the risk-reward profile appears unfavorable. Quality at 6.7/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Recursion Pharmaceuticals, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy RXRX stock right now?

Based on CirclFi's multi-model analysis, 1 of 9 models see upside for RXRX at $2.94. The models are divided, which means the investment case depends heavily on your assumptions about Recursion Pharmaceuticals, Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Recursion Pharmaceuticals, Inc.?

Key risks include: wide model disagreement (2353% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does RXRX compare to its competitors?

Among Biotechnology peers, RXRX holds a Quality Score of 6.7/10. Comparable companies include ADMA (QOC 10.0), CPRX (QOC 10.0), EXEL (QOC 10.0). The relative ranking helps investors identify whether RXRX offers better fundamental quality than alternatives in the same sector.

Is RXRX a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. RXRX's Quality Score of 6.7/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy RXRX at?

CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $0.12 to $2.98. At $2.94, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for RXRX.

View RXRX Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →